ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCAB Approves Call For New Efforts In Black/Hispanic Cancer

February 6, 1981

IOM appoints 22 to National Cancer Policy Forum.

July 1, 2005

Low-Dose Tamoxifen May Be Effective In Treating Breast Cancer, Study Finds

April 25, 2003

Garb Points Out Cancer Program Is Saving ore Lives a Year Than Polio Vaccine

April 6, 1979

Final Issue Of ‘77

December 16, 1977

Healy Comes To Defense Of NCI’s Robert Wittes; Official Has Been Target Of Innuendo Over Taxo

September 11, 1992